The trademark TRILIREB was filed by Regeneron Pharmaceuticals, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on March 31, 2020, and received one opposition filed on April 23, 2020 by BIOFARMA on Likelihood of confusion. the opponent was represented by CABINET GERMAIN & MAUREAU and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued April 23, 2020
The application was filed in English, and English was also language of all opposition proceedings (German was selected as the second language).